NCT00893373View on ClinicalTrials.gov

Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age

PHASE2CompletedINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

September 30, 2014

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

sorafenib

Standard AML chemotherapy plus sorafenib 400 mg BID

DRUG

placebo

Standard AML chemotherapy plus placebo

Trial Locations (9)

15236

Klinikum Frankfurt (Oder) GmbH, Frankfurt (Oder)

27356

Agaplesion Diakoniekrankenhaus Rotenburg, Rotenburg (Wümme)

28239

Ev. Diakonie-Krankenhaus gGmbH Bremen, Bremen

67655

Westpfalz-Klinikum GmbH, Kaiserslautern

70376

Robert-Bosch-Krankenhaus, Stuttgart

95445

Klinikum Bayreuth, Bayreuth

96049

Sozialstiftung Bamberg Klinikum am Bruderwald, Bamberg

Unknown

Charite Campus Benjamin Franklin, Berlin

01307

University Hospital Dresden, Dresden

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Technische Universität Dresden

OTHER